MPE announces partnership in EU consortium project CERTAINTY: advancing cancer care through virtual twins in personalised immunotherapyMyelomaDecember 19, 2023
ASH 2023 | Myeloma and AL amyloidosis updatesAL amyloidosis, Conferences, MPE, MyelomaDecember 15, 2023
EMA CHMP confirms recommendation for non-renewal of Blenrep marketing authorisationAccess, MPEDecember 15, 2023
Sign up for the MPE webinar on ASH 2023 myeloma and AL amyloidosis highlightsAL amyloidosis, Conferences, MPE, MyelomaDecember 9, 2023
The European Commission grants final approval for elranatamab for the treatment of relapsed or refractory myelomaAccess, MyelomaDecember 8, 2023
MPE launches a report focused on the impact of AL amyloidosis in quality of lifeAL amyloidosis, MPENovember 21, 2023
ESMO 2023 | Patient Advocacy Track highlights challenges in access, caregiver support and digitalisationConferences, MPEOctober 27, 2023
MPE launches European Amyloidosis Diagnosis Pathway to promote early detection of the rare diseaseAccess, AL amyloidosisOctober 26, 2023